Program FL9 is intended for laboratories that perform measurable (minimal) residual disease (MRD) testing (rare event analysis) for plasma cell myeloma.
Participation in this program alone does not satisfy PT requirements for laboratories performing more general analysis of leukemia/lymphoma specimens.
Program Information
Two 4.5‑mL specimens containing a cell line/whole blood mixture simulating plasma cell myeloma measurable (minimal) residual desease with clinical history and pertinent laboratory data
One online case with clinical history and gated dot plots
This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.
Help